Amphastar Pharmaceuticals Asset Turnover 2012-2025 | AMPH

Amphastar Pharmaceuticals asset turnover from 2012 to 2025. Asset turnover can be defined as the amount of sales or revenues generated per dollar of assets. The asset turnover ratio is an indicator of the efficiency with which a company is deploying its assets.
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.145B $0.732B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.196B 6.94
Dr Reddy's Laboratories (RDY) India $11.186B 20.30
BridgeBio Pharma (BBIO) United States $6.488B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.775B 14.41
Bausch Health Cos (BHC) Canada $1.663B 1.22
Personalis (PSNL) United States $0.445B 0.00
Taysha Gene Therapies (TSHA) United States $0.437B 0.00
Assembly Biosciences (ASMB) United States $0.093B 0.00
Sol-Gel Technologies (SLGL) Israel $0.022B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00